Amesh Adalja, of the University of Pittsburgh School of Medicine, told BioWorld Today that, although too early to tell for sure about toxicity, it’s “an encouraging sign” that Nabriva Therapeutics AG has chosen to develop lefamulin, a new antibiotic in the mushroom-derived pleuromutilin class that has shown a clean profile in phase II trials against skin infections.